SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin

Ryan D. Morin, Nathalie A. Johnson, Tesa Severson et al. · Nature Genetics · 2010 · 1.6K citations · Full text

Life Sciences, Genetics, Oncology +16

EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation

Wendy Béguelin, Relja Popovic, Matt Teater et al. · Cancer Cell · 2013 · 841 citations · Full text

Life Sciences, Genetics, Molecular Biology +12

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

Robert Marcus, Andrew Davies, Kiyoshi Ando et al. · New England Journal of Medicine · 2017 · 788 citations · Full text

Medicine, Immunology, Oncology +14

Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas

Christopher J. Sneeringer, Margaret Porter Scott, Kevin W. Kuntz et al. · Proceedings of the National Academy of Sciences · 2010 · 680 citations · Full text

Life Sciences, Genetics, Molecular Biology +17

Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study

Owen A. O’Connor, Barbara Pro, Lauren Pinter‐Brown et al. · Journal of Clinical Oncology · 2011 · 643 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15